|
|
|
|
|
Genzyme
|
|
Genzyme Corporation is one of the foremost biotechnological companies in the world today. Genzyme Corporation was established in Boston during 1981 and since then it has developed to the diversified enterprise achieving an annual revenues over 3 billion USD with the help of company’s work forces of over 9,500 heads working in different countries all over the world. They are integrated by a common goal of making the significant affirmative crash on the lives of people with unbearable ailments. Genzyme Corporation was selected by FORTUNE as one of the 100 best companies worth working with in the US during 2006-07.
Genzyme Corporation is the forerunner in the endurance of developing and applying most modern technologies in the fields of life sciences through several recognized products and services helping patients in almost 90 different countries across the globe today. The major products of the company chiefly focus on exceptionally hereditary ailments, kidney diseases, orthopedics, transplantation, cancer as well as various diagnostic testing. The company is dedicated to consistent advancements through the extensive research and development programs highlighting such sectors in addition to the immune disorders, contagious diseases and other sectors of deprived medical necessities. Genzyme maintains its drive towards its commitments to the patients and is working for developing medications, enhance its current therapies, obtain clearances for the new products all over the world and make certain that patients are given such treatments. The company is presently concentrating on its wide-ranging medication products like: Cerezyme, Ceredase, Febrazyme, Aldurazyme, Myozyme, MTAP – the Myozyme, Renagel, Hectorol, Synvisc, Carticel, Thymoglobulin, Campath, Clolar, Thyrogen and so on.
|
|
|
|
|
|
|
Taakeda Pharmaceutical Co
, Senkyo Co
, Baayer
, Kyowa Hako Kogyo
, Bohringer Ingelheim
, Pizer
, Schereeng_Plough
, Nowo Nordisk
, Sanophi Aventis
, Metsubishi Pharma
|
|
|
|
|
| Latest News About genzyme |
|
|
|
GENZYME gmbh. record reported yesterday second the quarter of INCOMES of $52.7... GENZYME is one of the nationand most largely and the most profitable biotechnology.....More |
|
|
|
|
16 -- Genentech inc. discarded a process, maintained, that demands yesterday Genzyme Corp.and interpretation of a 9 year old come off, under the Genzyme, that it. wäre...More |
|
|
|
|
Following acquisition of these shares, has Genzyme an obligatory. vollendet. Genzyme will use also to have shares AnorMED, that become of Nasdaq and the abregistriert, .....More |
|
|
|
|
A REPORT on GENZYME Corp.and enzyme treatment of Gaucherand illness, ... GENZYME retain please by, that the average costs of the therapy of an average of. sind...More |
|
|
|
|
Under contract conditions, ZymoGenetics GENZYME with genetically will furnish... GENZYME develops, manufactures and sells public health products to that.....More |
|
|
|
|
Led through the decision of GENZYME gmbh. to construct one $75 million production plant, ... GENZYME of executives, Boston official and the Massachusettss expressway.....More |
|
|
|
|
Genzyme said that the same Unterausschuss of the specialists that are convened to review around Fabrazyme and Replagal will, ... Genzyme develops that drug in partnership with BioMarin.....More |
|
|
|
|
GENZYME gmbh. of Boston said, signs that it a research two year-old collective and development. hat. GENZYME said, concentrate become that initially the two firms on use.....More |
|
|
|
|
GENZYME gmbh and Gov. Sweat seam said that they struck a BUSINESS, that convinced the Cambridge, ... GENZYME plans to reveal next week the place for the new PLANT, .....More |
|
|
|
|
GENZYME BUYS REAR RIGHTS, OF WYETH TO ANESTHETIZING. The GENZYME company said yesterday that it would buy BACK the RIGHTS, to sell and to bring on the market a joint inflammation painful, .....More |
|
|
|
|
|
|
|